Follow-up value of serum AFP and aminotransferases in chronic hepatitis B progression
Open Access
- 25 January 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13, 1082390
Abstract
Introduction: Chronic viral hepatitis (CH) is a stage prior to cirrhosis and primary cancer. Standard protocols for CH assessment during the long follow-up period are of great importance for precise treatment and living quality improvement. In this study, we aimed to analyze multiple serum indexes in chronic hepatitis B (CHB)-infected patients and to discuss their combined values in clinical applications.Methods: Total 503 lines of laboratory data from 2012 to 2021 were extracted from103 CHB patients who were followed-up in our hospital. They were divided into the remission group and the progression group according to their complete clinical information and laboratory data. A series of models of serum indexes were analyzed to illustrate the fluctuation trend of @ach index in a time-dependent manner.Results: The models revealed that abundant serum alpha-fetoprotein (AFP) in the remission group was characteristically associated with hepatocyte destruction markers aspartate aminotransferase (AST) and alanine aminotransferase and favored a much longer progression-free period (P 0.0001). A model-derived equation consisting of serum AFP and AST values showed a good performance (83% reliability) to distinguish the two groups.Discussion: This study clearly demonstrates the intrinsic quantitative relationship between serum AFP and liver aminotransferases involving antivirus treatment response. The model-based equation compensates for serum hepatitis B virus DNA detection during outpatient follow-up and it may serve as a useful laboratory tool for CHB progression assessment.Keywords
This publication has 42 references indexed in Scilit:
- Clinical profile and predictors of mortality in patients of acute-on-chronic liver failureDigestive and Liver Disease, 2012
- Zhx2 and Zbtb20: Novel regulators of postnatal alpha-fetoprotein repression and their potential role in gene reactivation during liver cancerSeminars in Cancer Biology, 2011
- Alpha-fetoprotein and prognosis in acute liver failureLiver Transplantation, 2006
- Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2006
- Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injuryHepatology, 2004
- Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2004
- Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV statusJournal of Hepatology, 2001
- A Model to Predict Survival in Patients With End–Stage Liver DiseaseHepatology, 2001
- α-fetoprotein: Reevaluation in hepatologyHepatology, 1990
- The development of cirrhosis in patients with chronic type B hepatitis: A prospective studyHepatology, 1988